Top 50 Health Care Startup Investors in Switzerland (July 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Zürcher Kantonal Bank
VC Fund
|
60 | Switzerland, Germany, Japan | Seed, Series A | Health Care, Biotechnology, Medical Device | $1.2M–$13M |
|
Foundation for Innovation and Technology (FIT)
VC Fund
|
43 | Switzerland, France, United States | Debt Financing, Grant, Seed | Health Care, Biotechnology, Artificial Intelligence | $13k–$1.2M |
|
Verve Ventures
VC Fund
|
41 | Switzerland, Germany, France | Series A, Seed, Series B | Health Care, Software, Biotechnology | $1.4M–$45M |
|
SICTIC
VC Fund
|
19 | Switzerland, Germany, Tanzania | Seed, Pre-Seed | Software, Artificial Intelligence, Information Technology | $302k–$3M |
|
BioMedPartners
VC Fund
|
18 | Switzerland, Germany, France | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $4.9M–$83M |
|
VI Partners
VC Fund
|
16 | Switzerland, Germany, United States | Series A, Series B, Seed | Health Care, Biotechnology, Software | $1.3M–$41M |
|
Kickfund
VC Fund
|
13 | Switzerland, Germany | Seed, Pre-Seed, Convertible Note | Biotechnology, Manufacturing, Medical | $110k–$5.7M |
|
redalpine
VC Fund
|
13 | Germany, Switzerland, United Kingdom | Seed, Series A, Series B | Biotechnology, Health Care, Software | $1.6M–$60M |
|
Eclosion SA
VC Fund
|
12 | Switzerland | Seed, Series C | Biotechnology, Pharmaceutical, Health Care | $1.6M–$28M |
|
HTGF (High-Tech Gruenderfonds)
VC Fund
|
11 | Germany, Switzerland, United States | Seed, Series A | Software, Biotechnology, Information Technology | $1.1M–$33M |
|
M Ventures
VC Fund
|
10 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
4FOX Ventures
VC Fund
|
10 | Switzerland | Series A, Seed, Series B | Medical, Health Care, Biotechnology | $2.1M–$69M |
|
Bernina BioInvest
VC Fund
|
10 | Switzerland | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $1.7M–$65M |
|
Schroder Adveq
VC Fund
|
10 | Switzerland, United States, India | Series B, Series C, Series A | Biotechnology, Health Care, Therapeutics | $5.6M–$100M |
|
StartAngels Network
VC Fund
|
9 | Switzerland, Brazil | Seed, Series A, Series B | Medical, Health Care, Medical Device | $933k–$6.1M |
|
Kinled Holding
VC Fund
|
9 | United Kingdom, United States, Switzerland | Seed, Series A | Biotechnology, Health Care, Software | $500k–$43M |
|
Novartis Venture Fund
VC Fund
|
9 | United States, Switzerland, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $5.1M–$120M |
|
OCCIDENT
VC Fund
|
8 | Switzerland, Germany, Finland | Series A, Seed, Series B | Health Care, Biotechnology, Medical Device | $874k–$139M |
|
Founderful
VC Fund
|
8 | Switzerland, United Kingdom, Canada | Pre-Seed, Seed, Series A | Software, Artificial Intelligence, Information Technology | $1.2M–$24M |
|
GoBeyond
VC Fund
|
8 | Switzerland, Germany, United Kingdom | Seed, Series A | Information Technology, Medical, Software | $544k–$10M |
|
3wVentures
VC Fund
|
8 | Switzerland, Spain, Austria | Seed, Angel, Series A | Software, Health Care, Medical | $50k–$8M |
|
S2S Ventures
VC Fund
|
7 | Switzerland, Germany | Pre-Seed, Seed | Health Care, Artificial Intelligence, Manufacturing | $28k–$3.4M |
|
Swisscom Ventures
VC Fund
|
7 | Switzerland, United States, United Kingdom | Series B, Series A | Software, SaaS, Information Technology | $1.8M–$60M |
|
Zühlke Ventures AG
VC Fund
|
7 | Switzerland, Sweden, United States | Series A, Seed, Series B | Health Care, Medical Device, Medical | $1.2M–$11M |
|
Fongit Seed Invest
VC Fund
|
7 | Switzerland | Seed, Series A, Series B | Health Care, Medical, Biotechnology | $1.2M–$3.7M |
|
EQT Life Sciences
VC Fund
|
7 | United States, The Netherlands, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $6.9M–$165M |
|
b2venture
VC Fund
|
7 | Germany, Switzerland, United Kingdom | Series A, Seed, Series B | Software, Health Care, Information Technology | $1.3M–$52M |
|
BlueOcean Ventures
VC Fund
|
7 | Switzerland, India, France | Seed, Series A, Series B | Health Care, Medical, Personal Health | $1M–$20M |
|
Novo Holdings
VC Fund
|
7 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $9M–$135M |
|
Sofinnova Partners
VC Fund
|
7 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $6.6M–$109M |
|
Lichtsteiner Foundation
VC Fund
|
7 | Switzerland | Seed, Series A | Biotechnology, Health Care, Medical | $1.6M–$6.8M |
|
Polytech Ventures
VC Fund
|
7 | Switzerland, United States, Spain | Seed, Series A | Financial Services, FinTech, Software | $1M–$9.7M |
|
Versant Ventures
VC Fund
|
7 | United States, Switzerland, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $4.7M–$108M |
|
Alpana Ventures
VC Fund
|
6 | United States, Switzerland, Germany | Seed, Series A | Software, FinTech, Information Technology | $850k–$14M |
|
Privilège Ventures
VC Fund
|
6 | Switzerland, Italy, France | Seed, Series A | Software, Health Care, Hardware | $1.2M–$7M |
|
Innosuisse
VC Fund
|
6 | Switzerland, United States, United Kingdom | Grant, Pre-Seed, Seed | Health Care, Biotechnology, Medical Device | $17k–$16M |
|
Nina Capital
VC Fund
|
5 | United States, United Kingdom, Germany | Seed, Pre-Seed, Series A | Health Care, Artificial Intelligence, Software | $573k–$21M |
|
ETH Zurich Foundation
VC Fund
|
5 | Switzerland | Seed, Pre-Seed, Grant | Information Technology, Medical, Software | $162k–$5.8M |
|
Joyance Partners
VC Fund
|
5 | United States, Germany, United Kingdom | Seed, Series A, Pre-Seed | Health Care, Biotechnology, Wellness | $425k–$13M |
|
Pureos Bioventures
VC Fund
|
5 | France, Switzerland, United States | Series A, Series B, Series C | Biotechnology, Therapeutics, Medical | $6.6M–$125M |
|
Ralph Gygax
Angel
|
5 | Switzerland | Seed, Pre-Seed, Series A | Cannabis, Wellness, Cosmetics | $127k–$641k |
|
New Enterprise Associates
VC Fund
|
4 | United States, India, United Kingdom | Series A, Series B, Series C | Software, Health Care, Biotechnology | $5.4M–$103M |
|
Aravis Ventures
VC Fund
|
4 | Switzerland, United States, Denmark | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | |
|
Index Ventures
VC Fund
|
4 | United States, United Kingdom, France | Series A, Series B, Seed | Software, E-Commerce, Internet | |
|
Ertan Wittwer
Angel
|
4 | Switzerland, United States | Seed, Angel, Pre-Seed | Health Care, Water, Beauty | |
|
Startfeld
VC Fund
|
4 | Switzerland | Seed | Health Care, Wellness, Medical | |
|
EFI Lake Geneva Ventures
VC Fund
|
4 | Switzerland, Germany | Seed, Pre-Seed, Series B | Health Care, Medical, Life Science | |
|
Werner Hoffmann
Angel
|
4 | Switzerland | Seed, Series A | Cannabis, Wellness, Cosmetics | |
|
Translink Capital
VC Fund
|
4 | United States, China, South Korea | Series A, Series B, Series C | Software, Information Technology, Artificial Intelligence | $4M–$58M |
|
Neomed Management
VC Fund
|
4 | Switzerland, United States, Italy | Series B, Series C | Health Care, Biotechnology, Medical | $10M–$65M |
| Access all 1078 investors in Switzerland Health Care startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Zürcher Kantonalbank is an independent, incorporated public-law institution is its public service mandate. Enshrined in law, it governs the bank's economic, social, and environmental commitment.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Seed, Series A
- Geography: Switzerland, Germany, Japan
Investor stats
- Total investments: 195
- Round size: Seed $1.2M–$6M; Series A $2.3M–$13M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- Riverkin — Riverkin builds rugged, low-cost water sensor systems for rivers that measure turbidity and temperature in real time. Our platform turns field data into clear insights and decision making tools.
- QualySense — QualySense is a Swiss start-up company focused on innovative high-throughput grain, beans and seeds sorting technology. QualySense develops a high-speed multi-tons per hour sorting device, which will change how grains, beans and seeds are processed and valued worldwide by assessing the biochemical quality of grains one by one. The QualySensesorters will enable customers to separate grain batches into different biochemical quality classes and sell the corresponding premium products at higher average prices. Food processors will be able to considerably increase the production value, and produce higher quality products in a non-interrupted process.
- Pearltec AG — Headquartered in Schlieren / Zurich, Pearltec AG develops, produces and delivers solutions for the optimal storage, fixation and positioning of patients. Their products are based on unique, patented technology developed in collaboration with ETH Zurich and renowned university hospitals.They have set theirselves the goal to use the technologycompetence of Pearltec AG for the benefit of humans, animals and industry and to create added value for their customers by excellent quality and convincing application advantages.Pearltec AG is certified according to ISO standard 13485. This certification certifies that their quality management system for the development and manufacture of medical devices meets the highest international standards.
The Foundation for Technology Innovation gives financial assistance to creative and technological projects at various phases of development. FIT funds projects in energy and the environment, information and digital technology, life sciences and health, precision industries, and nutrition and agriculture.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Artificial Intelligence
- Stage:Debt Financing, Grant, Seed
- Geography: Switzerland, France, United States
Investor stats
- Total investments: 196
- Round size: Seed $117k–$1.2M; Grant $13k–$125k; Debt Financing $107k–$583k
- Lead/follow: 93% lead, 7% follow
Portfolio highlights
- MyStones — MyStones turns athlete health and performance data into actionable insights, preventing injuries and strengthening collaboration between athletes, coaches, and physiotherapists.
- Skilder Ai — skilder is an Agent Skills Management Platform that organizes and governs how teams use AI assistants like Claude, ChatGPT, and Microsoft Copilot.
- Isospec Analytics — Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are unlocking the potential of glycomics and metabolomics in disease biomarker discovery and for the development of safer nutritional and pharmaceutical products.
Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: Switzerland, Germany, France
Investor stats
- Total investments: 273
- Round size: Seed $1.4M–$12M; Series A $2.6M–$18M; Series B $4.2M–$45M
- Lead/follow: 14% lead, 86% follow
- Last fund: Likely still investing — raised $66M in 2022
Portfolio highlights
- Kiutra — We provide cryogen-free cooling systems that simplify low-temperature research. Our solutions offer fast cooldowns, automated control and millikelvin performance ideal for quantum technologies and material science.
- Sleepiz — Sleepiz is a Zürich based startup with the aim to enable the medical community to take healthcare into the home environment. Sleepiz provides an easy and comfortable to use solution with a device that is simply placed on the bedside table. The device operates in a non-contact fashion and measures movements originating from heart contractions andbreathing patterns as well as body motions with medical grade accuracy.By making use of wireless millimeter wave technology, sensor fusion and artificial intelligence Sleepiz will in the future not only able to diagnose sleep disorders, but also to perform long-term monitoring. Thereby, the progression of chronic diseases can be monitored to allow faster intervention and better treatment.
- Clinpal — Backed by over 30 years of scientific discovery and validation, Cambridge Cognition offers the end-to-end platform for CNS clinical trials.
SICTIC is the leading angel investor network in Switzerland with the largest Swiss seed-stage startup dealflow.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Pre-Seed
- Geography: Switzerland, Germany, Tanzania
Investor stats
- Total investments: 210
- Round size: Seed $583k–$3M; Pre-Seed $302k–$2.1M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- Agrinorm — Agrinorm is a Swiss deep tech company leveraging cutting edge machine learning techniques for the optimization of fruits and veg supply chains.
- hypt — hypt is a Swiss based SaaS marketing solution that empowers companies to digitalize word-of-mouth. By using our word-of-mouth manager companies are able to activate 40% of their customers to send out a personal recommendation to their peers increasing sales through word-of-mouth by 4 times. Our solution empowers our ICP customers in the finance andinsurance segments to strategically use and optimize the most authentic and cost effective advertising channel – word-of-mouth – and makes it an accessible asset of every marketing mix.
- Get More Brain — Digital learning platform connecting learners and their employers with teachers and schools, publishers and EdTech companies. Marketplace for learning content and learning related services.
BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: Switzerland, Germany, France
Investor stats
- Total investments: 87
- Round size: Series A $5.5M–$31M; Series B $4.9M–$83M; Series C $5.8M–$48M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — raised $113M in 2018
Portfolio highlights
- T-CURX — T-CURX is a biotechnology company focused on the development of personalized cancer immunotherapies. Utilizing a proprietary platform, T-CURX aims to advance the field of T cell therapies to address the challenges faced in treating various cancers. The company's innovative approach involves the creation of a new generation of T cells designedto improve patient outcomes. As a spin-out from the University Clinics Würzburg, Germany, T-CURX leverages the expertise of its co-founders, including Prof. Michael Hudecek, to pioneer in the area of CAR-T cell-based medicines. With a commitment to transforming cancer treatment, T-CURX is at the forefront of developing targeted therapies that offer hope for a more effective and personalized approach to cancer care.
- iDEL Therapeutics — iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism.
- ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
Vi Partners is a venture capital firm backing exceptional founders in healthcare and technology across Switzerland and Europe for over 25 years.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Series B, Seed
- Geography: Switzerland, Germany, United States
Investor stats
- Total investments: 111
- Round size: Seed $1.3M–$6.5M; Series A $3.7M–$24M; Series B $3.3M–$41M
- Lead/follow: 24% lead, 76% follow
- Last fund: May invest from a new fund soon — raised $117M in 2020
Portfolio highlights
- Equippo.com — Used construction equipment marketplace. Easy and safe. Only inspected machines. Worldwide delivery. Money Back Guaranteed. Buy Now, Pay Later!
- Nexthink — Discover what your employees need, see what they experience, know how they feel. Deliver IT that delights.
- Pay by Shopping (deal united) — paybyshopping.com Domain Name is available to Buy. Grab this great Domain from Daaz. Daaz has the lowest transaction fees in the industry. See our list of GTLD's,CCTLD's, New GTLD's,3N's, 6N's, 3L's, 6L's etc.
Kickfund is a Venture Capital fund that systematically backs companies that successfully complete Venture Kick.
Show more...Investment focus
- Industry: Biotechnology, Manufacturing, Medical
- Stage:Seed, Pre-Seed, Convertible Note
- Geography: Switzerland, Germany
Investor stats
- Total investments: 47
- Round size: Seed $1.1M–$5.7M; Pre-Seed $335k–$4.4M; Convertible Note $110k–$118k
- Lead/follow: 17% lead, 83% follow
Portfolio highlights
- SolidWatts — We electrify industrial process heating by creating the new state-of-the-art in microwave and radio frequency power sources for industry.
- Cosaic — Cultivated - Creamy, dairy-free indulgence
- BLEEDnFIRE Therapeutics — BLEEDnFIRE Therapeutics: At BLEEDnFIRE Therapeutics, we are pioneering innovative siRNA-based therapies for hemophilia, Von Willebrand disease & other rare bleeding disorders (RBDs) by developing BnF-001. Our mission is to transform patient care and improve quand improve quality of life through targeted ...
redalpine is a thesis-driven vc with deep expertise in software and science. since 2006. we believe in the power of big ideas and in empowering game changers. we don't just invest, we co-create a better tomorrow. together with you.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A, Series B
- Geography: Germany, Switzerland, United Kingdom
Investor stats
- Total investments: 191
- Round size: Seed $1.6M–$13M; Series A $3.2M–$31M; Series B $15M–$60M
- Lead/follow: 39% lead, 61% follow
- Last fund: May invest from a new fund soon — raised $25M in 2013
Portfolio highlights
- 9fin — The leading AI-powered debt market intelligence platform. Real-time news, data, and analytics across LevFin, private credit, and distressed debt.
- Luya Foods — Sustainable food, Plant-based, Circular food, Meat alternative, Alternative to meat, Okara, Food waste, and Fermentation
- Carvolution — Carvolution is the next-generation mobility services provider reshaping car ownership through its fully digital subscription service.Carvolution makes choosing a new car exciting. As it removes the hassle out of ownership and the inflexibility out of leasing, it enables consumers to choose their dream car as a convenient monthly subscriptionservice instead of a long-term commitment. Their digitally-powered one-stop-shop streamlines everything from insurance to maintenance: saving customers time and money while enabling efficiencies for all connected parties.
Eclosion assists entrepreneurs with the necessary resources to bridge the gap between their laboratories and the stage where the start-up
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Health Care
- Stage:Seed, Series C
- Geography: Switzerland
Investor stats
- Total investments: 16
- Round size: Seed $1.6M–$2.7M; Series C $20M–$28M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- KYLYS — KYLYS is an innovative Swiss company based in Geneva founded in March 2017. KYLYS provides people and patients with highly effective and safe products based on biomolecules.
- Genkyotex — Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
- MPC Therapeutics — MPC Therapeutics develops a novel class of compounds with application in Immunotherapy and Metabolic diseases
High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Series A
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 587
- Round size: Seed $1.1M–$7.3M; Series A $3.5M–$33M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — raised $522M in 2022
Portfolio highlights
- Selfapy — Selfapy offers a therapy support tool that helps recognize negative patterns of thought and train new behavior. Selfapy is your guided, self-help online course against depression with a personal psychologist as a companion.
- Verovaccines — VEROVACCiNES discovers and develops innovative vaccine solutions, to protect animals against infectious diseases. Key is a novel, broadly applicable, yeast-based technology to generate subunit marker vaccines. This technology has been validated by demonstrating protection of several target animal species against different viral diseases(proof-of-concept).VEROVACCiNES GmbH is a spin-off company of the Martin Luther University Halle-Wittenberg, Germany in 2017. The company exclusively took over IP, brand, team, products and know-how from the former BMBF GO-Bio-funded VEROVACCiNES project at Halle University. VEROVACCiNES GmbH is eligible for follow-up phase 2 funding from the same BMBF GO-Bio program. They cooperate closely with veterinary pharmaceutical companies, universities and research institutes, and they are eager to initiate new collaborations.
- OMEICOS Therapeutics — OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activatean endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 171
- Round size: Seed $2.4M–$22M; Series A $5.6M–$49M; Series B $15M–$100M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
- Future Fertility — OUR AI-POWERED ASSESSMENTS GUIDE PERSONALIZED FERTILITY TREATMENT DECISIONS IN OVER 180 CLINICS ACROSS 32 COUNTRIES
- ApoGen Biotechnologies — ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapieseventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.
4FO Ventures
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: Switzerland
Investor stats
- Total investments: 20
- Round size: Seed $2.1M–$3.6M; Series A $2.1M–$15M; Series B $6.4M–$69M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Positrigo — NeuroLF is an ultra-compact brain Positron Emission Tomography system. Our technology makes functional imaging accessible for people worldwide.
- Ecorobotix — ecoRobotix contributes to an agriculture that respects the environment, focusing on soil and hydrological resources conservation and using a minimum amount of energy. ecoRobotix aims to offer precise, safe, reliable and affordable robotic solutions that simplify farmers’ life to produce healthy food. In particular, its revolutionary solar-poweredweeding robot offers a more sustainable use of herbicides while reducing farmers costs.
- Neo Medical — Neo aims at transforming the current approach to spinal surgery by providing a unique answer to the worldwide strive for healthcare cost optimization through efficient, versatile and high quality systems.
Bernina BioInvest is an investment Firm.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: Switzerland
Investor stats
- Total investments: 11
- Round size: Seed $1.7M–$20M; Series A $17M–$65M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- Versameb — Versameb AG is a preclinical-stage biopharmaceutical company located in Basel, Switzerland managed by an experienced scientific and business pharmaceutical industry team. The company’s focus is the development of novel RNA-based therapeutics. Versameb’s proprietary VERSagile technology platform enables efficient development of functional mRNAmolecules for customized protein expression and modification in multiple disease areas with high unmet medical need.
- HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
- Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.
Schroders Capital provides investors with access to a broad range of private asset investment opportunities, portfolio building blocks and customised private asset strategies. With over $65 billion assets under management, we offer a diversified range of investment strategies, including real estate, private equity, secondaries, venture capital, infrastructure, securitised products and asset-based finance, insurance-linked securities and impact investing.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series C, Series A
- Geography: Switzerland, United States, India
Investor stats
- Total investments: 36
- Round size: Series A $5.6M–$23M; Series B $11M–$83M; Series C $15M–$100M
- Lead/follow: 11% lead, 89% follow
- Last fund: May invest from a new fund soon — raised $113M in 2020
Portfolio highlights
- Bizongo — Bizongo is a Tech-Enabled B2B Platform for Packaging, Apparels & Other Customised Goods. We digitally transform vendor management & supply chain.
- HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
- Memo Therapeutics — Memo Therapeutics AG translate immune responses into superior medicines. Our best-in-class antibodies transform lives of patients with viral infections & cancer
StartAngels Network is a Zurich-based angel investment firm that provides investment consulting services.
Show more...Investment focus
- Industry: Medical, Health Care, Medical Device
- Stage:Seed, Series A, Series B
- Geography: Switzerland, Brazil
Investor stats
- Total investments: 27
- Round size: Seed $933k–$3.7M; Series A $2.1M–$3.7M; Series B $1.7M–$6.1M
- Lead/follow: 26% lead, 74% follow
Portfolio highlights
- Calingo — Calingo is a digital insurance platform that offers personalised and optimised risk protection at the point of sale.
- Scanvio — Scanvio Medical provides gynecologists, endometriosis centers and ultrasound manufacturers with an AI-guided ultrasound software for faster endometriosis diagnosis.
- Hylomorph — Hylomorph is a clinical-stage medical device company developing innovative materials designed to transform the biocompatibility of implantable medical devices.
Kinled was founded in 1980 to retain the investment assets of the Aisher family.In 1990, the investment focus shifted to a portfolio of early stage investments applying Kinled’s company development experience alongside the endurance and passion of family owned investments together with the strategic focus of venture capitalists.Since then,Kinled has taken 8 companies to public markets and many more to successful trade sales at significant multiples.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Switzerland
Investor stats
- Total investments: 133
- Round size: Seed $500k–$11M; Series A $2M–$43M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Esper — Esper is the first cloud-based platform to help governments proactively manage public policy with better data and transparency.
- Varda — Expanding the economic bounds of humankind with the world's first orbital manufacturing & reentry platform.
- PreComb — PreComb develops technologies to optimally adapt the therapies to each patient for difficult to treat cancers to increase the success rates in cancer therapy. Only an efficient use of healthcare resources can lead to a maximum improvement in the quality of life of patients.
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 217
- Round size: Series A $5.1M–$81M; Series B $11M–$120M; Series C $9M–$75M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $200M in 2009
Portfolio highlights
- Splice Bio — Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
- Bionano Genomics — Discover how Bionano is striving to elevate health and wellness for all through optical genome mapping (OGM) solutions that transform the way the world sees the genome.
- Protego Biopharma — Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California.
Occident is an international, privately held investment company based in Zug and Munich. Our goal is to manage our own wealth in a sustainable, meaningful manner seeking to make a positive contribution to society through our investments. Venture Capital is the focus of our investment activities. We see ourselves as a long-term oriented enabler forinnovative start-ups and visionary founders. As a complementary team of experts, we are fascinated by technologically sound topics (deep tech) from the life sciences, digital and high-tech sectors with the potential to decisively improve people's lives.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Seed, Series B
- Geography: Switzerland, Germany, Finland
Investor stats
- Total investments: 33
- Round size: Seed $874k–$5.2M; Series A $2.1M–$16M; Series B $6.2M–$139M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Lymphatica Medtech — Lymphatica Medtech is a medical device development company developing a minimally invasive solution for chronic lymphedema.Lymphedema is the chronic swelling that generally occurs in the arms or the legs.Lymphedema is most commonly caused by the removal of or the damage to the lymph nodes as a part of cancer treatment. It results from ablockage in the lymphatic system, which is part of the immune system. The blockage prevents the lymphatic system from draining excess fluids, and the fluid buildup leads to swelling, infections, and pain.Unfortunately, there is no cure for lymphedema. It can be managed with early diagnosis and diligent care of the affected limb, through daily compression, bandages, and manual drainage sessions. From the moment of the diagnosis, the life of lymphedema patients changes forever.Cancer and cancer-related interventions (i.e. surgery, radiotherapy) are frequent causes of lymphedema occurring both in the upper and lower limbs. Breast cancer survivors are at high risk for developing lymphedema, as well as patients treated for melanoma, pelvic and head and neck cancer or other cancer treatments that require lymph node dissection. Physical trauma can also result in lymphedema, a major cause of lymphatic disease among wounded veterans.Lymphedema is associated with significantly impaired quality of life, skin changes, increased risk of infection and in rare cases lymphedema itself may undergo malignant transformation.Lymphatica offers a permanent solution that will allow patients to regain their normal lifestyle.
- Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
- Lunaphore — Lunaphore Technologies is a spatial biology company, building multiplex immunofluorescence & IHC solutions for discovery and immuno-oncology research
Founderful operates as a venture capital firm and a Switzerland’s leading pre-seed fund.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Pre-Seed, Seed, Series A
- Geography: Switzerland, United Kingdom, Canada
Investor stats
- Total investments: 101
- Round size: Seed $1.5M–$16M; Pre-Seed $1.2M–$3.8M; Series A $3.4M–$24M
- Lead/follow: 55% lead, 45% follow
- Last fund: Likely still investing — raised $85M in 2024
Portfolio highlights
- AVIAN —
- Calvin Risk — We help companies manage the risks of their AI algorithms!
- Stellar Alpina — Stellar Alpina is a Zurich-based space propulsion startup developing rotating detonation rocket engines for mobility after launch.
GoBeyond is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders.Its clients are individuals, familyoffices, professional groups and corporations. It is active in the EU, Switzerland and the US. GoBeyond also offers educational training modules for angel investors in 11 categories.
Show more...Investment focus
- Industry: Information Technology, Medical, Software
- Stage:Seed, Series A
- Geography: Switzerland, Germany, United Kingdom
Investor stats
- Total investments: 163
- Round size: Seed $544k–$5M; Series A $1.2M–$10M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Fastree3D — Fastree3D imaging sensors help recognize and measure distance to fast moving objects in real-time, enabling driving assistance or autonomous navigation. Fastree3D SA is a fabless semiconductor company, spin-off from EPFL Lausanne, Switzerland founded in September 2013 (UID CHE-291.330.490). The company subsidiary Fastree3D B.V. performs researchwith TU-Delft, Netherlands (KvK 58866973).
- Spyra One — Single Shot Technology | Tactical display | Automatic Refill | Power Shot SpyraTwo - the world's strongest water gun! Start epic water battles with the only water gun in the world that features our patented Single-Shot-Technology, fully automatical pump, a hightech tactical display and the Power Shot for extra impact.
- DomoHealth — Join us in revolutionizing patient care using the power of AI-assisted digital health platform and safety solutions. Enhancing digital health with the best platform, application and devices for the direct benefits of patients and healthcare professionals.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!3wVentures provides seed money and venture capital to international internet startups. As they focus on early stage projects and prototypes, our investments and co-investments target a volume of up to USD 250,000.
Show more...Investment focus
- Industry: Software, Health Care, Medical
- Stage:Seed, Angel, Series A
- Geography: Switzerland, Spain, Austria
Investor stats
- Total investments: 42
- Round size: Seed $50k–$3.8M; Angel $583k–$2.1M; Series A $1.2M–$8M
- Lead/follow: 2% lead, 98% follow
- Last fund: May invest from a new fund soon — raised $100M in 1999
Portfolio highlights
- Abionic — Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abionic uses these highly advanced technologies to provide the medical profession with a novel diagnostic tool designed to give patients personal allergyprofiles. Abionic aims to become an important international player in the field of personalized medicine, in particular in allergy detection.Abionic SA is a certified ISO 9001/13485 company, including research, development and commercialization of in vitro diagnostic devices for allergies detection. The standard ISO 13485 specifies requirements for a quality management system where an organization has to demonstrate its ability to provide medical devices and related services that consistently meet customer and regulatory requirements.Abionic SA is a privately owned high-tech company and is strongly supported by the Swiss Federal Institute of Technology of Lausanne (EPFL), The Canton of Vaud and Venturelab.Abionic was founded by former scientists from the biomedical optics laboratory (LOB) at EPFL. Its headquarters are located in Lausanne, Switzerland.Abionic appreciates the support it has received from:
- GUURU Solutions — Discover how community-powered advice can turn your PDPs into trusted, high-converting content and get cited in AI search.
- Pregnolia — Pregnolia ensures that every woman can have a happy, healthy and informed pregnancy until term. Their team knows that the existing research about preterm birth assessment is very promising, but this alone does not guarantee success. Sabrina, Francisco and Annette are highly committed to develop the commercial version of the device, complete theclinical trial, follow the regulatory roadmap and execute on their business vision to successfully support gynaecologists in improving the preterm birth risk assessment and birth management.
S2S Ventures is a fully student-led VC fund from Switzerland, backed by some of the country's most successful entrepreneurs.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Manufacturing
- Stage:Pre-Seed, Seed
- Geography: Switzerland, Germany
Investor stats
- Total investments: 27
- Round size: Seed $954k–$3.4M; Pre-Seed $28k–$2.9M
- Lead/follow: 26% lead, 74% follow
- Last fund: Likely still investing — raised $13M in 2021
Portfolio highlights
- Haicker — Haicker is an AI-driven cybersecurity platform designed to automatically detect vulnerabilities in web application codebases with exceptional precision. Leveraging advanced Large Language Model (LLM)-based agents, Haicker outperforms traditional security testing solutions by removing false positives and providing actionable insights that helpdevelopers fix vulnerabilities swiftly and confidently.Traditional static (SAST) and dynamic (DAST) application security testing tools typically suffer from high rates of false positives, demanding significant manual review efforts from developers and security teams. Haicker addresses this core challenge through its unique architecture: all issues are validated against a replica of the application, allowing Haicker to filter real findings from hallucinations.Initially proven in competitive cybersecurity environments like Capture-the-Flag (CTF) competitions, Haicker quickly demonstrated superior performance and reliability on open source projects. Its capabilities extend beyond vulnerability scanning, integrating seamlessly into common development workflows, including continuous integration and delivery pipelines.Haicker's scalable architecture ensures enhanced performance as computational resources and AI models evolve and become more cost-effective. By leveraging a distributed approach where multiple AI agents concurrently analyze the same piece of code, Haicker ensures comprehensive vulnerability detection with unprecedented depth and efficiency.Targeted at security-conscious enterprises, software development teams, and DevSecOps practitioners, Haicker empowers organizations to shift security left, integrating deep vulnerability detection early into the development lifecycle. Its intuitive interface and streamlined integration capabilities with leading code management platforms such as GitHub, GitLab, and Bitbucket enable effortless adoption.Founded in Switzerland by cybersecurity and web development experts, Haicker is positioned to transform the application security market by offering a smarter, faster, and more reliable alternative to manual penetration tests and legacy automated scanning solutions.
- Scanvio — Scanvio Medical provides gynecologists, endometriosis centers and ultrasound manufacturers with an AI-guided ultrasound software for faster endometriosis diagnosis.
- Forgis — Forgis is leading the next industrial revolution by introducing industrial intelligence into factories, which boosts the competitiveness of Western manufacturing.
Swisscom Ventures is an venture capital arm of Swisscom AG, that specializes in early stage tech investments founded in 2007.Swisscom Ventures invests in growth companies with emerging business models and technologies of strategic relevance to Swisscom's core business. As a value-add investor, Swisscom brings its investees the technicalexpertise and strategic insights of an incumbent telecom operator. We act as a bridge to Swisscom's operational business units, which portfolio companies can also leverage as a test environment for their products and services.Swisscom Ventures seeks minority stakes in companies related to the information/communications/entertainment space.
Show more...Investment focus
- Industry: Software, SaaS, Information Technology
- Stage:Series B, Series A
- Geography: Switzerland, United States, United Kingdom
Investor stats
- Total investments: 143
- Round size: Series A $1.8M–$23M; Series B $2.3M–$60M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely still investing — raised $300M in 2022
Portfolio highlights
- Apono — Apono makes permission management to applications, infrastructure, and data repositories simple, secure and compliant.
- Billogram — Since its start in 2011, Billogram has revitalized the outdated invoicing process by offering companies with recurring payments an intelligent digital platform. Using smart technology, we help companies strengthen their customer relations while also automating payment processes in a way that lowers costs, increases revenue, and reduces churn. Theresult is a payment that pays off for everyone.
- Bring! Labs — Bring! Labs is an app for multi-device use that accompanies the user through all aspects of shopping for groceries and other everyday items. It offers grocery shopping for millions of people with shared shopping lists, integrated recipes, online shopping, local offers, and loyalty cards. Bring! Labs offers innovative mobile advertising platforms tocompanies in the retail and FMCG.
Zühlke Ventures AG is a venture capital arm of Zühlke Technology Group AG specializing in financing of start-ups at an early stage and providing growth capital. It seeks to invest in the technology and medical devices companies. It typically invests in German-speaking Europe and Great Britain.
Show more...Investment focus
- Industry: Health Care, Medical Device, Medical
- Stage:Series A, Seed, Series B
- Geography: Switzerland, Sweden, United States
Investor stats
- Total investments: 12
- Round size: Seed $1.2M–$3M; Series A $7M–$11M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Evismo — Diagnosing arrhythmias, sleep apnea, and stress directly in your practice. Digitally and efficiently. For general practitioners and specialists in Switzerland.
- Healios AG — Healios CTMS provides the Digital Biomarker based technology and digital validation scales to improve and streamline research and clinical practice.
- PeriVision — At Perivision, we combine artificial intelligence (AI), virtual reality (VR) and the cloud to build the next generation systems to understand visual function. Our systems improve workflow efficiency in practices and hospitals and provide deeper clinical insight into eye diseases.
Fongit Seed Invest (FSI) is the leading Seed Money Fund of Switzerland for young technology companies. It provides smart seed capital.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: Switzerland
Investor stats
- Total investments: 9
- Round size: Seed $1.2M–$1.4M; Series A $2.3M–$3.7M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- EBAMed — EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware andsoftware components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.
- Gmelius — Gmelius is the world's first 360 email collaboration platform designed for Gmail and your company's daily apps. Join the async movement!
- Annaida Technologies — Empowering fertility providers and researchers with AI-driven metabolomic platforms. Non-invasive, real-time insights at the microscale for personalized medical treatments.
Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, The Netherlands, Switzerland
Investor stats
- Total investments: 182
- Round size: Series A $6.9M–$77M; Series B $12M–$110M; Series C $12M–$165M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $266M in 2023
Portfolio highlights
- LUMA Vision — OneProjects is an Irish-German cardiac imaging specialist.
- Neurent Medical — Discover NEUROMARK, a minimally invasive solution for Chronic Rhinitis that targets the posterior nasal nerve to provide lasting symptom relief.
- Rotation Medical — Rotation Medical Inc. manufactures and markets a collagen scaffold for rotational cuff disease in Minnesota. The company was formerly known as Denali Medical Inc. and changed its name to Rotation Medical Inc. in March 2010. Rotation Medical was founded in 2009 and headquartered in Plymouth, Minnesota.
B2venture is a venture capital firm focused on early-stage investments in digital and industrial technology companies. B2venture invests EUR 100m+ per year in high-growth companies with ticket sizes from EUR 0.25m to 3.5m.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Series A, Seed, Series B
- Geography: Germany, Switzerland, United Kingdom
Investor stats
- Total investments: 235
- Round size: Seed $1.3M–$9M; Series A $4M–$22M; Series B $8M–$52M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — raised $135M in 2021
Portfolio highlights
- Kiin Bio — Drug discovery is a system problem, where every inefficiency amplifies the next. We have the solution.
- Kubermatic — Easily manage multiple Kubernetes clusters with the automation power of the Kubermatic platform. Scale your business with reliability.
- Calvin Risk — We help companies manage the risks of their AI algorithms!
BlueOcean Ventures SA provides capital, operational and company development advisory support (mentoring, company management, divestment experience, network, negotiation support) to entrepreneurs in Switzerland. BlueOcean Ventures is based in Geneva, Switzerland.
Show more...Investment focus
- Industry: Health Care, Medical, Personal Health
- Stage:Seed, Series A, Series B
- Geography: Switzerland, India, France
Investor stats
- Total investments: 17
- Round size: Seed $1M–$3M; Series A $2.3M–$20M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Augurix — Just another WordPress site
- Mikajaki — Mikajaki is an innovative automated multi-patient ocular diagnostics platform. The platform enables the use of digital technology, robots, AI, and data, allowing patients and eye specialists access to the specific treatment they require. Mikajaki is currently collaborating with ophthalmology clinic groups across the world to test and implementEyeLib.
- official.fm — At Official.fm, they develop powerful music promotion tools for you, whether you're an emerging artist or an accomplished label.They make it easy to manage a few tracks or a large catalog, create pages and players that look like you and share them across your favorite promotion platforms and social networks, all the while collectinginsightful analytics. Improving your workflow is their top priority.Promoting your music with official.fm will always be free. Music promotion is an investment for you and it is one for us too. Now you also have the ability to sell directly music to your fans. Soon they will offer more ways for your to generate revenue from your music.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 351
- Round size: Series A $9M–$125M; Series B $13M–$135M; Series C $30M–$118M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- Biosyntia — Biosyntia is a biotech startup within synthetic biology and metabolic engineering. We develop biocatalysts at an unprecedented speed and efficiency by employing our patent pending high-throughput screening technology.By developing tailored processes based on biocatalysis, Biosyntia enables production of complex chemical compounds byfermentation. Biocatalysis may substantially reduce both production costs and environmental impact compared to other processes such as chemical synthesis. We partner with manufacturers of fine chemical compounds (flavors, fragrances, APIs, pigments, additives, intermediates, and more) in order to establish more sustainable manufacturing processes for a greener tomorrow.Biosyntia is located at the Novo Nordisk Foundation (NNF) Center for Biosustainability in Hørsholm, 25 kilometers north of Copenhagen.
- IVERIC bio — IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inheritedretinal diseases.
- Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 319
- Round size: Series A $6.6M–$70M; Series B $10M–$109M; Series C $12M–$100M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- Myricx Bio — Myricx Pharma is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across other diseases.
- GFBiochemicals — GFBiochemicals is the only company to produce levulinic acid at commercial scale directly from biomass.In 2008, a group of biobased chemical experts saw the significant potential of levulinic acid to replace petroleum-based products across a range of market sectors. GFBiochemicals was founded to develop the production technology needed for thisrevolution in chemicals and biofuels.GFBiochemicals demonstrated these breakthrough technologies in the Caserta plant, in partnership with the University of Pisa and the Polytechnic University of Milan. This commercial-scale plant was retrofitted with new conversion, recovery and purification technology.
- Forth Therapeutics — Forth Therapeutics is a biotechnology company dedicated to advancing precision treatments for fibrosis.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Boosting health pioneers. We invest in early stage start-ups in different sectors: medtech, life science, biotech, mental health, public health, well-being.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: Switzerland
Investor stats
- Total investments: 10
- Round size: Seed $1.6M–$6.8M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- Hemostod — Developing universal platelets and next-generation diagnostics
- DigeHealth — DigeHealth's approach to monitoring gut health using bowel noises and body measurements could provide some really valuable insights into digestive well-being.
- Allegria Therapeutics — Allegria Therapeutics operates as a biotech company.
Polytech Ventures are an early stage VC firm based in Switzerland with a strong international focus. Their strategic location at EPFL in Lausanne grants us access to one of the most dynamic and recognized innovation centers in the world
Show more...Investment focus
- Industry: Financial Services, FinTech, Software
- Stage:Seed, Series A
- Geography: Switzerland, United States, Spain
Investor stats
- Total investments: 50
- Round size: Seed $1M–$5M; Series A $2.3M–$9.7M
- Lead/follow: 26% lead, 74% follow
- Last fund: May invest from a new fund soon — raised $40M in 2016
Portfolio highlights
- Relai — All you need to get started is to download our award winning Relai app, complete a simple verification and start buying with as little as 50 CHF/EUR.
- Hemostod — Developing universal platelets and next-generation diagnostics
- Earny — Payroll management built for Startups & SMEs. Swiss payroll service with no hidden fees & no hassle
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, Canada
Investor stats
- Total investments: 287
- Round size: Series A $4.7M–$84M; Series B $10M–$105M; Series C $12M–$108M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Graphite Bio — Graphite Bio is a next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases
- Lycia Therapeutics — Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA.
- Nested Therapeutics — Nested Therapeutics is a Cambridge-based VC-backed stealth biotech company. The company's focus is on finding and creating new precision oncology small-molecule drugs targeted toward cancer genes. Nested Therapeutics was established in 2021 in Cambridge, Massachusetts.
Alpana Ventures is a Swiss VC focusing on digital transformation.Since 2016 we backed 45 founder teams with 3 Funds, supporting them in their journey towards a positive impact.Committed to value creation, we discover deep tech solutions in Switzerland, Europe and the US.We invest to embed them into innovative business models and back them tobecome global market leaders.Applying ESG criteria, our portfolio companies help create a more sustainable future.
Show more...Investment focus
- Industry: Software, FinTech, Information Technology
- Stage:Seed, Series A
- Geography: United States, Switzerland, Germany
Investor stats
- Total investments: 98
- Round size: Seed $850k–$4M; Series A $2.3M–$14M
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- Sinay — Use the full potential of your data with intelligent solutions. Become more efficient on a daily basis and reduce your environmental impact.
- Nezasa — Discover how to grow your business with Nezasa TripBuilder, the world's leading travel commerce solution for travel businesses.
- Tinamu — Trusted inventory intelligence delivered in real-time
Where Entrepreneurs Thrive Rooted in reality, reaching for the extraordinary over five decades of combined investment experience Where Entrepreneurs Thrive Rooted in reality, reaching for the extraordinary Authentic, dedicated, disciplined, and goal-oriented, our team drives meaningful and lasting success About Team
Show more...Investment focus
- Industry: Software, Health Care, Hardware
- Stage:Seed, Series A
- Geography: Switzerland, Italy, France
Investor stats
- Total investments: 18
- Round size: Seed $1.2M–$5.3M; Series A $4.1M–$7M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- Xsensio — Xsensio develops the unique Lab-on-Skin™ sensing platform to sense in real-time biochemical information at the surface of the skin, providing unprecedented real-time information about our health and wellness, in a simple and non-invasive way.The Xsensio Lab-on-Skin™ sensing chip relies on a unique, highly-miniaturized sensing platform developedat the Nanolab of the Swiss Federal Institute of Technology. By leveraging semiconductor properties, our sensing platform unleashes a whole new set of possibilities in continuous health monitoring.
- ENANTIOS — ENANTIOS specializes in creating benchtop analytical instruments that provide industries, research institutions, and academic facilities.
- Hydromea — Hydromea is a Swiss company with core expertise in underwater robotics, through-water wireless communication networks and underwater navigation.
Innosuisse’s role is to promote science-based innovation in the interests of industry and society in Switzerland.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Grant, Pre-Seed, Seed
- Geography: Switzerland, United States, United Kingdom
Investor stats
- Total investments: 233
- Round size: Seed $500k–$16M; Grant $30k–$2.7M; Pre-Seed $17k–$4.3M
- Lead/follow: 79% lead, 21% follow
Portfolio highlights
- OrthoSens — OrthoSens develops battery-free sensors that turn standard orthopedic implants into smart, data-driven devices. Unlike existing smart implant solutions that require an implanted battery making them too large and too risky to scale beyond large joints, OrthoSens moves all electronics outside the body. A paper-thin sensor integrates directly intoexisting implants with no battery, no surgical workflow change and zero explant risk. An external wearable powers the sensor wirelessly and collects real-time data on load, micromotion and bone fusion. The result is a footprint 250x smaller than battery-powered competitors, opening up additional spine, foot & ankle markets that existing solutions cannot address. The clinical need is clear: approximately 20% of post-surgical patients drive around 68% of total post-operative costs through missed complications, continuous implant monitoring exists to catch them earlier. Starting January 2026, 745 US hospitals enrolled in CMS's mandatory TEAM bundle are now accountable for 30-day episode costs, creating direct institutional demand for this data.OrthoSens generates revenue through three streams: sensor sales to orthopedic implant manufacturers (unlocking +$1,309 NTAP reimbursement per unit), a SaaS subscription capturing 40% of Medicare's $104/month RPM reimbursement per patient and post-market data analytics. The company has validated its technology across 3 functional prototypes, filed 2 core patents with favorable Freedom to Operate and secured $1.3M+ in non-dilutive funding. It is raising a $2.3M seed round to complete ISO-13485 certification, conduct the FDA pre-clinical study and file a 510(k) submission. The team is led by Gwenael Hannema (3x medtech founder), Dr. Oleg Kotsur (Head of R&D), and key employees, supported by experienced board members with leadership backgrounds at Novartis, Medtronic and J&J MedTech.
- Chiral — Next-generation electronics with nanomaterials
- BLEEDnFIRE Therapeutics — BLEEDnFIRE Therapeutics: At BLEEDnFIRE Therapeutics, we are pioneering innovative siRNA-based therapies for hemophilia, Von Willebrand disease & other rare bleeding disorders (RBDs) by developing BnF-001. Our mission is to transform patient care and improve quand improve quality of life through targeted ...
We deploy early stage capital to fuel the growth of need-driven health technology companies.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 89
- Round size: Seed $2M–$6.3M; Pre-Seed $573k–$2.4M; Series A $5M–$21M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Navidence — Navidence provides a transformative Real World Evidence (RWE) Design platform that enables organizations to efficiently adapt to the ever-increasing ecosystem of Real World Data (RWD) sources. The company unlocks the power of Computable Operational Definitions (CODefs) for RWE Design and RWD Assessment. Navidence's RWE Sherpa platform offerstools to streamline the process of defining an RWE study's data, making it easier for researchers to conduct their studies in the age of data.
- Rivia — Integrated Clinical Trial Intelligence. Drive therapeutic evaluation and trial management with real-time insights.
- Ladder Health — Ladder Health offers virtual pediatric therapy and support for early childhood developmental delays, including speech and physical therapy.
ETH Zurich Foundation is an independent, non-profit-making foundation under private law for the promotion of education and research at ETH Zurich.
Show more...Investment focus
- Industry: Information Technology, Medical, Software
- Stage:Seed, Pre-Seed, Grant
- Geography: Switzerland
Investor stats
- Total investments: 21
- Round size: Seed $1.1M–$5.8M; Grant $162k–$175k; Pre-Seed $473k–$4.4M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- FenX — FenX is a recyclable insulating product that turns mineral waste into usable resources to support a circular economy. Real estate developers, construction companies, and architects can now access non-flammable insulation materials for construction processes. the company's portfolio of recyclable insulation materials, which includes foamproducts and foam formulations made from readily available waste or natural materials with CO2 emissions.
- Soverli —
- Tethys Robotics — Tethys Robotics develops AI-powered application oriented robotics system that enables professionals in carrying underwater search & recovery to inspection & surveillance.
Joyance Partners invests in companies that, through science and tech, cultivate joy to improve how we live, focusing on the health and consumer sectors from Pre-Seed to Series A.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Wellness
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Germany, United Kingdom
Investor stats
- Total investments: 107
- Round size: Seed $750k–$5.2M; Pre-Seed $425k–$2M; Series A $3.6M–$13M
- Lead/follow: 7% lead, 93% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Oga — Fun Dance App.
- KilgourMD — KilgourMD develops hair and scalp care products for reducing shedding and supporting scalp health. They formulate topical serums and treatment solutions. Their products address hair loss prevention and scalp maintenance.
- Lucky Energy — LUCKY F*CK is a better-for-you energy drink company.
Venture capital for companies developing innovative therapeutics.
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Medical
- Stage:Series A, Series B, Series C
- Geography: France, Switzerland, United States
Investor stats
- Total investments: 34
- Round size: Series A $15M–$123M; Series B $6.6M–$100M; Series C $22M–$125M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — raised $205M in 2020
Portfolio highlights
- Adcytherix — Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer.
- Tavo Biotherapeutics — Tavo Biotherapeutics is a biotech company that develops injection therapies for eye diseases.
- PulseSight Therapeutics — PulseSight is an ophthalmology drug development company creating novel, non-viral gene therapies with minimally invasive delivery technology to address the unmet need for treatments against severe retinal diseases leading to blindness.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Ralph Gygax is a Chief Administrative Officer at SWISS Gate AG. He attended KV, SVIT from 1999 to 2007.
Show more...Investment focus
- Industry: Cannabis, Wellness, Cosmetics
- Stage:Seed, Pre-Seed, Series A
- Geography: Switzerland
Investor stats
- Total investments: 5
- Round size: Seed $127k–$641k
- Lead/follow: 100% lead, 0% follow
Portfolio highlights
- SWISS Gate AG — SWISS Gate AG is a family-run Swiss company founded in November 2019 by brothers Dominic, Marco & Michael Hoffmann with the support of their father Werner Hoffmann and uncle Ralph Gygax.SWISS Gate AG focuses with its positioning on the areas of Lifestyle & Wellbeing. The offered product assortment ranges from CBD Anti-Aging and Day Creamsto Skin Creams as well as Shampoo, Shower Gel or Conditioner to Hemp Foods like Hemp Tea or Hemp Seed Oils to CBD Hemp Flowers to CBD Hemp Oil for humans and animals.SWISS Gate AG exclusively distributes its products of the company-owned brands Herbalea and Old Donald's through selected resellers as well as through the company-owned e-commerce channel cbuy.ch - Alles Gute aus Cannabis.SWISS Gate AG manufactures all products together with exclusive partners from the cosmetics, food & consumer goods industry and has the exclusive production & distribution rights over the products.SWISS Gate AG has launched its Series A financing round in mid-September 2021 with the goal to raise CHF 5'000'000. Currently, CHF 200,000 of this amount has been raised. The financing round is currently open - interested parties can contact CEO Marco Hoffmann directly via the contact details.
Foundational partners to ambitious founders at every stage of company-building.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1581
- Round size: Series A $5.4M–$60M; Series B $10M–$77M; Series C $14M–$103M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely still investing — raised $2.8B in 2022
Portfolio highlights
- IonQ — Working to build the world's best quantum computers to solve the world's most complex problems
- Spyglass Ophthalmics — A vision towards a higher quality of life!
- Xenon Pharmaceuticals — A leading neuroscience company forging new paths for those living with neurological and psychiatric disorders.
Aravis is the first independent Swiss on-shore private equity house, an established investor in the renewable energy and life science spaces. We are a "hands-on" investor taking leading positions and understanding the balance between finance, commercial assets and people. With this distinct and crafted approach, we are serving over 30leading investors including corporates, pension funds, government funds, insurance companies and family offices. Currently actively managing more than a quarter of a billion Swiss francs, we have a cumulative history of investments in over 100 companies. These have resulted in several noticeable exits including the divestment of several renewable energy companies and a number of life science reverse take-overs, listings and trade sales. Our many years of experience in the Swiss fund industry have enabled us to establish a platform with a comprehensive offering of investment, accounting, regulatory and reporting expertise. Located in Zurich, Aravis was founded in 2001.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: Switzerland, United States, Denmark
Investor stats
- Total investments: 19
- Lead/follow: no public data
Portfolio highlights
- Bird Rock Bio — We are a biopharmaceutical company focused on the development of proprietary cannabinoid derivatives for the treatment of glaucoma and other diseases with significant unmet medical needs. Our innovative approach to drug development combines strong science with the drive to find solutions where the need is the greatest.
- Synaffix BV — Synaffix BV is a clinical-stage, Netherlands-based biotech company that has established a proprietary antibody-drug conjugate (ADC) technology platform that enhances efficacy and tolerability compared to all 3 major clinical-stage ADC technologies. We have a 'one-stop' technology offering (including 4 different ADC payloads) thatenables the development of proprietary ADCs from any antibody and our patent portfolio provides patent protection of resulting Products through at least 2035.Our business model is technology out-licensing and we regularly engage in research collaborations with other companies that are interested in developing highly competitive ADC products for their own pipelines.Disclosed partnerships to date include those with ADC Therapeutics and Mersana Therapeutics
- Hedera-22 — Hedera-22 expanded its scope to include the identification of natural products through the use of in-house bio-informatic prediction technologies.
Index Ventures is an international venture capital firm with dual headquarters in San Francisco and London, investing in technology-enabled companies with a focus on e-commerce, fintech, mobility, gaming, infrastructure/AI, and security.
Show more...Investment focus
- Industry: Software, E-Commerce, Internet
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 1013
- Lead/follow: no public data
Portfolio highlights
- BIT ODD — Gaming company building games filled with wonder, weirdness and delight
- Dream Games — Join Dream Games and explore a vibrant universe of characters and puzzles. Discover why millions of players worldwide love our mobile games. Visit us to learn more about our games, company culture, and career opportunities.
- Acutus Medical — Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists.Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Itsproducts are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals.It was founded in 2011 and headquartered in Carlsbad, California.
Ertan Wittwer is the Founder and Board Member bestsmile. He attended BBZ Uzwil.
Show more...Investment focus
- Industry: Health Care, Water, Beauty
- Stage:Seed, Angel, Pre-Seed
- Geography: Switzerland, United States
Investor stats
- Total investments: 7
- Lead/follow: no public data
Portfolio highlights
- Noriware — Noriware wants to revolutionize the packaging industry by offering a truly sustainable, home-compostable alternative to traditional plastic, through unlocking the potential of seaweed. In doing so, we want to be the leader in transparency to motivate the industry to become more sustainable.
- Alpine White — Alpine White is a healthcare startup that manufactures personal care products and treatments for its consumers. They exist to keep teeth healthy and white through great products and services that empower people to feel confident and feel good.
- Everyman Health — Everyman Health ist Spezialist für Männergesundheit und bietet wissenschaftlich fundierte Lösungen für Männer aller Altersgruppen. In Zusammenarbeit mit unseren Partnern, bieten wir dir ein umfassendes Portfolio von digitalen, medikamentösen und nicht-medikamentösen Therapien für unterschiedliche Männerprobleme.Über unsere Plattform wirst du inwenigen Minuten mit einem Schweizer Facharzt verbunden und erhältst eine persönliche Diagnose und gegebenenfalls ein Rezept.Auf Wunsch wird deine persönliche Behandlung von einer lizenzierten Schweizer Apotheke diskret verpackt und dir kostenlos bis vor die Haustür geliefert.
Startfeld is the innovation and start-up network in the St.GallenBodenseeArea. In every phase of innovation, they support both ambitious entrepreneurs and established SME, who are open to new impulses and development.
Show more...Investment focus
- Industry: Health Care, Wellness, Medical
- Stage:Seed
- Geography: Switzerland
Investor stats
- Total investments: 4
- Lead/follow: no public data
Portfolio highlights
- Nahtlos — Nahtlos is a developer of a textile ECG carrier without glue intended to provide long-term, continuous monitoring of heart activity. In order to create a modular and highly flexible ECG system, the company's device consists of a ribbon carrier with clip-in electrodes that are based on a patented electrode structure that can be easily adjustedto different body shapes. This allows doctors to increase patient comfort by swapping out the conductive gel used in gel electrodes.
- OnlineDoctor — OnlineDoctor is an innovative Swiss-based platform that allows the user to diagnosed any skin problems quickly (within 48h), location-independent and cost-effectively by an independent dermatologist. OnlineDoctor is suitable for the evaluation of all kinds of skin problems such as rash, eczema, birthmark and many more. The company'suncomplicated, high-quality platform provides a service that benefits all parties.
- Health Yourself — Health Yourself is making routine healthcare services available digitally and from home. So far, we are offering lab tests from home, medication subscriptions and personalised supplements for health concerns ranging from sexual health to prevention.
EFI Lake Geneva Ventures is a seed and early-stage investment strategy based in Geneva, Switzerland. Founded in 2020, our mission is to foster innovation by investing at an early stage in fast-growing innovative Swiss companies in Technology, Life Sciences and Medtech.
Show more...Investment focus
- Industry: Health Care, Medical, Life Science
- Stage:Seed, Pre-Seed, Series B
- Geography: Switzerland, Germany
Investor stats
- Total investments: 6
- Lead/follow: no public data
Portfolio highlights
- EBAMed — EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware andsoftware components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.
- Hylomorph — Hylomorph is a clinical-stage medical device company developing innovative materials designed to transform the biocompatibility of implantable medical devices.
- Annaida Technologies — Annaida Technologies has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies.
Professional experience: Expert for Risk Management and Public Relations Strategic & operational responsibility Compliance & Safety Management Decades of leadership experience as colonel & professional military pilot in the Swiss Air Force
Show more...Investment focus
- Industry: Cannabis, Wellness, Cosmetics
- Stage:Seed, Series A
- Geography: Switzerland
Investor stats
- Total investments: 4
- Lead/follow: no public data
Portfolio highlights
- SWISS Gate AG — SWISS Gate AG is a family-run Swiss company founded in November 2019 by brothers Dominic, Marco & Michael Hoffmann with the support of their father Werner Hoffmann and uncle Ralph Gygax.SWISS Gate AG focuses with its positioning on the areas of Lifestyle & Wellbeing. The offered product assortment ranges from CBD Anti-Aging and Day Creamsto Skin Creams as well as Shampoo, Shower Gel or Conditioner to Hemp Foods like Hemp Tea or Hemp Seed Oils to CBD Hemp Flowers to CBD Hemp Oil for humans and animals.SWISS Gate AG exclusively distributes its products of the company-owned brands Herbalea and Old Donald's through selected resellers as well as through the company-owned e-commerce channel cbuy.ch - Alles Gute aus Cannabis.SWISS Gate AG manufactures all products together with exclusive partners from the cosmetics, food & consumer goods industry and has the exclusive production & distribution rights over the products.SWISS Gate AG has launched its Series A financing round in mid-September 2021 with the goal to raise CHF 5'000'000. Currently, CHF 200,000 of this amount has been raised. The financing round is currently open - interested parties can contact CEO Marco Hoffmann directly via the contact details.
Translink Capital is a trailblazing Silicon Valley VC with unmatched institutional connections to Asia's economic powerhouses.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Series A, Series B, Series C
- Geography: United States, China, South Korea
Investor stats
- Total investments: 163
- Round size: Series A $4M–$27M; Series B $9.9M–$42M; Series C $10M–$58M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- Luxul Technology — Awoken by environmental concerns and dreams to shine the world, Luxul Technology Inc. was established in 2010 in Santa Clara, California, to provide customers with high quality LED lamps to save energy bill and installation cost.Our EazyLux T5 and T8 LED Lamps are the world’s first LED tube lights that are fully compatible with existingfluorescent lamps using E-ballasts. Through our devoted efforts, we have made this dream come true: long life LED lamps that are extremely easy to install while reducing your energy bill by 50%. Founded by James Pan, Ph.D. of Stanford University, our research and development teams in the US and Taiwan consists of the most dedicated engineers from all disciplines: such as electrical, optical, mechanical, software, graphic and art designs. Backed by more than 50 worldwide patents, our goal is to apply world class technologies to lighting products that benefits everyone’s life while conserving our environment. Luxul’s products represent Quality, Beauty and Simplicity.With increasing demand in the US and Mexico, we are expanding our manufacturing facilities and sales offices in the US and Mexico.
- Adwo Media Holdings Develops mobile advertising platform best mobile marketing services — Beijing Adwo Mobile Media Technology Ltd. develops mobile advertising platform. The company was founded in 2010 and is based in Beijing, China.
- Winking Entertainment — Headquartered in Singapore. Winking Studios is one of the largest game art outsourcing and game development studios globally.
NeoMed Management is an international venture capital investment firm, exclusively focused on the healthcare industry. Founded in 1997, NeoMed has established five funds to date.NeoMed invests in emerging companies with outstanding growth prospects. These companies are developing innovative and proprietary medical products that addresssubstantial market opportunities in the pharmaceutical, medical device and diagnostics industries.NeoMed has a multi-stage investment approach and invests at all stages of development from start-up to later stage growth financings. Since inception, NeoMed has successfully invested in more than 30 companies in Europe, including Scandinavia, Switzerland, Germany and the UK, and in North America.From offices in Norway and Switzerland, NeoMed’s experienced investment team works closely with its entrepreneurs and a broader industry network to support the growth of its portfolio companies.NeoMed is currently focusing on NeoMed Innovation IV L.P. and NeoMed Innovation V L.P.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series C
- Geography: Switzerland, United States, Italy
Investor stats
- Total investments: 40
- Round size: Series B $20M–$65M; Series C $10M–$44M
- Lead/follow: 15% lead, 85% follow
Portfolio highlights
- Sonendo — Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely usedendodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.
- Oxular — Oxular is a clinical-stage retinal therapeutics company that is developing technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs.
- JenaValve Technology — Redefining what it means to treat patients with severe aortic regurgitation.
Health Care Investor funding in Switzerland at a glance
Stats across 1.5k deals from 1.1k investors.
Access all 1078 investors in Switzerland Health Care startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Health Care Investors in Switzerland investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 1078 investors investing in Switzerland Health Care startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!